ADMA
ADMA BIOLOGICS, INC.
Key Financials
Operating Income
$191.4M
↑ 37.7%
Net Income
$146.9M
↓ 25.7%
Gross Profit
$292.8M
↑ 33.3%
Total Assets
$624.2M
↑ 27.7%
Revenue
$510.2M
↑ 19.6%
EPS (Diluted)
$0.60
↓ 25.9%
Total Liabilities
$146.9M
↑ 5.2%
Shareholders' Equity
$477.3M
↑ 36.8%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| 4 | 5/14/2026 | View on SEC |
| 4 | 5/12/2026 | View on SEC |
| 10-Q | 5/6/2026 | View on SEC |
| 8-K | 5/6/2026 | View on SEC |
| 8-K | 5/4/2026 | View on SEC |
| SCHEDULE 13G | 4/29/2026 | View on SEC |
| ARS | 4/15/2026 | View on SEC |
| DEFA14A | 4/15/2026 | View on SEC |
| DEF 14A | 4/15/2026 | View on SEC |
| 4 | 4/3/2026 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | ADMA |
| Company Name | ADMA BIOLOGICS, INC. |
| CIK | 1368514 |
| Sector | Biological Products, (No Diagnostic Substances) |
| Industry | Large accelerated filer |
| Exchange | Nasdaq |
| SIC Code | 2836 |
| SIC Description | Biological Products, (No Diagnostic Substances) |
| Entity Type | operating |
| Fiscal Year End | 1231 |
| State of Incorporation | DE |
| Phone | (201) 478-5552 |